Subscribe
zerbor
4 June 2018Big Pharma

French court knocks out Gilead Truvada SPC

The Paris Court of First Instance has nullified a supplementary protection certificate (SPC) covering Gilead’s HIV/AIDS treatment Truvada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
French court refuses MSD injunction request in SPC clash
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.
Europe
Gilead HIV drug not entitled to SPC, says UK court
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
French court refuses MSD injunction request in SPC clash
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.
Europe
Gilead HIV drug not entitled to SPC, says UK court
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,

More on this story

Big Pharma
French court refuses MSD injunction request in SPC clash
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.
Europe
Gilead HIV drug not entitled to SPC, says UK court
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court